Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth ConferenceAdicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30 a.m. ETThe live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc.Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc.Investor and Media ContactsAnne Bowdidgeabowdidge@adicetbio.comPenelope BelnapPrecision AQPenelope.belnap@precisionaq.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260721675362/en/
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth ConferenceAdicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30 a.m. ETThe live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc.Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc.Investor and Media ContactsAnne Bowdidgeabowdidge@adicetbio.comPenelope BelnapPrecision AQPenelope.belnap@precisionaq.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260721675362/en/
